Skip to main content
Premium Trial:

Request an Annual Quote

Lynx Expands, Accelerates Takara Agreement

NEW YORK, Jan. 9-Japan's Takara Bio has expanded its license agreement with Lynx Therapeutics, Lynx said today.

 

Under the original agreement, signed in November 2000, Takara received exclusive rights for five years to use Lynx's proprietary cloning and expression technologies (Megaclone, Megasort and Massively Parallel Signature Sequencing) for discovery services and microarray development in Japan, Korea, China and Taiwan.

 

In the newly expanded agreement, Takara's exclusive rights to these technologies in those countries is expanded through the life of the patents. The Japanese firm also secures the nonexclusive right to provide genomic discovery services in France and Italy, an agreement that entitles Lynx to royalties.

 

In return, Takara has advanced its fee payment and stock purchase schedule. A payment to Lynx scheduled for 2003 was made in December 2002. Payments slated for 2004 and 2005 will also be moved forward.

 

Because the company's stock has traded below $1.00 since July 31, Lynx received a Nasdaq delisting warningon Dec. 13. The company said in December it would appeal the notice, and is "exploring various alternatives" to avoid being removed from the exchange.

The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.